Medicure Inc. (MCUJF)
Medicure Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Winnipeg, MB, CA. The stock last traded at $0.85, up 0.00% on the session, giving a market capitalisation of $8.9M. On trailing twelve-month figures it carries a trailing P/E of -2.11, a net margin of -21.7%. Its beta of 1.04 implies it has historically moved more than the broad market.
Medicure Inc. operates as a biopharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the cardiovascular market, primarily serving Canada and the United States. Among its key offerings is AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist specifically designed to manage acute coronary syndrome, encompassing conditions like unstable angina and non-Q-wave myocardial infarction. The company also distributes ZYPITAMAG, a medication aimed at treating patients suffering from primary hyperlipidemia or mixed dyslipidemia. Additionally, Medicure provides ReDS, an innovative non-invasive medical device that facilitates the measurement of lung fluid, aiding in the effective management of congestive heart failure. Furthermore, its portfolio includes Sodium Nitroprusside injection, utilized for multiple critical applications: reducing elevated blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension to minimize surgical bleeding, and addressing acute congestive heart failure. These products are made available to consumers through both traditional retail pharmacies and online channels. Established in 1997, the company maintains its corporate headquarters in Winnipeg, Canada.
Medicure Inc. is most often compared with the following Healthcare names: